Beigene Ltd., of Waltham, Mass., part of Beigene Co. Ltd., of Beijing, named Ji Li executive vice president, global head of business development. Previously, Li was vice president of business development and licensing at Merck Research Laboratories, a subsidiary of Merck & Co. Inc., where he was responsible for business development activities of late-stage inbound and outbound opportunities. Read More

Jiangsu Hengrui Medicine Co. Ltd., of Lianyungang, China, and the University of Texas MD Anderson Cancer Center said they entered a three-year agreement for translational research to develop rational combination therapies and personalized medicines as well as to identify new treatment opportunities, especially in the field of immuno-oncology. Read More

HONG KONG – India’s dependence on China for pharmaceutical raw materials is threatening the country’s health care industry and pushing the government to take action. Read More

HONG KONG – Having been developing basic fibroblast growth factor (bFGF) products for more than 25 years, China’s Essex Bio-technology Ltd. (HK:1061) has earned a leading position in the ophthalmology biopharmaceutical space. Now the company is looking to expand its offerings by moving into the rapidly growing monoclonal antibody space. Read More

HONG KONG – A study by Taiwanese researchers has demonstrated that two glycoproteins are highly expressed in glioblastoma multiforme (GBM) cancer stem cells, and they play a key role in the tumorigenicity of the brain cancer. Both represent promising new potential therapeutic targets against the largely incurable disease. Read More

NEW DELHI – India’s revised draft guidelines for biosimilars have drawn mixed reactions. The country’s pharma industry has, in broad strokes, welcomed the increased clarity and more rigorous conditions in the revised guidelines, but the Organisation of Pharmaceutical Producers of India, comprising largely foreign pharma firms, said the new rules could compromise patient safety. Read More

In an economy driven by global competition, counterfeits and theft of trade secrets remain major hazards for U.S. drug and device companies, handing them an uneven playing field in some parts of the world. Read More